Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-06-20

Clinical Trial Update: Dasatinib in Polycythemia Vera [Phase 2]

View source ↗

Summary

A Phase 2 trial of dasatinib in polycythemia vera was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sprycel (dasatinib)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Polycythemia Vera | Phase 2 | Status: TERMINATED | Results posted: 2017-06-20